Clinical Trial

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-08-20; most recent amendment 2024-10-10.
Status change: Recruiting → Active, Not Recruiting 2024-10-10
Status change: Not Yet Recruiting → Recruiting 2020-09-09
Trial Details
NCT Number NCT04523272
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Renal Cancer
Enrollment 528 participants
Start Date 2020-08-25
Primary Completion 2025-06 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-15